DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20163205

Role of myeloid growth factors in chemotherapy induced neutropenia

Ravinutala Srinath Bharadwaj, Donepudi Aruna

Abstract


Neutropenia is a major dose limiting toxicity of many chemo therapeutic regimens. Haemopoietic colony - stimulating factors (CSFs) have been shown to reduce the duration and severity of chemotherapy induced neutropenia (CIN) and risk of febrile neutropenia. Supportive care with myeloid growth factors improve chemotherapy delivery by minimizing chemotherapy dose reductions or treatment delays by enabling the delivery of full dose chemotherapy (dose dense) in short time intervals. The goal of this article is to give comprehensive review of current literature regarding medical practice guidelines and risk assessment models for appropriate use of myeloid growth factors and management of febrile neutropenia.


Keywords


CIN, CSFs, Dose dense chemotherapy

Full Text:

PDF

References


Nirenberg A, Bush AP, Davis A, Friese CR, Gillespie TW, Rice RD. Neutropenia: state of knowledge part-1. Onco Nurs For. 2006;33(6):1193-201.

Coates TD. Over view of nutropenia in children and adolescents, 2014. Available at www. Uptodate.com.

Devita, Hellman, Rosenberg. Cancer principles and practice of oncology, phildelphia: Lippincott Williams and Wilkins, 10th edition; 1964:65.

de Naurois J, Novitzky- Basso I, Gill MJ, Marti FM, Cullen MH, Roila F. ESMO guidelines working group. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010;21(5):252-6.

Dale DC. Colony stimulating factors for the management of neutropenia in cancer patients. Drugs. 2002;62(1):1-15.

Vogel CL, Wojtukiewicz, Carroll RR, Tjulandin SA, Barajas Figuerora LJ, Wien BL, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multi-center, double blind, placebo controlled phase 3 study. J Clin Oncol. 2005;23:1178-84.

Culakova E, Thota R, Poniewieski MS, Kuderer NM, Wogu AF, Dale DC, et al. Patterns of chemotherapy- associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med. 2014;3:434-44.

Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H, et al. Risk and consequences of chemotherapy induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract. 2015;10:47-54.

Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of low - risk sub group at presentation. Arch Intern Med. 1988;148:2561-68.

Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the multinational association of supportive care of cancer (MASCC) risk index score. Supp Car Canc. 2004;12:555-60.

Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclo-phosphomide, methotrexate and fluorouracil in node- positive breast cancer: the results of 20 years follow- up. N Engl J Med. 1995;332:901-6.

National comprehensive cancer network: NCCN Clinical practice guidelines in oncology: fever and neutropenia. Available at http://www.nccn.org/professionals/physician_gls/PDF/fever.pdf.

Goodman and Gilman. Pharmacological basis of therapeutis, Mc Graw Hill publishers, 12th edition; 2011:1068:1072-75.

Thomas J, Liu F, Link DC. Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor. Curr Opin Hemat. 2002;9(3):183-9.

Schneider A, Krüger C, Steigleder T, Weber D, Pitzer C, Laage R, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clini Invest. 2015;115(8):2083-98.

Pitzer C, Krüger C, Plaas C, Kirsch F, Dittgen T, Müller R, et al. Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain. 2008;131(Pt 12):3335-47.

Wong GG, Witek JS, Temple PA, Wilkens KM, Leary AC, Luxenberg DP, et al. Human GM- CSF: molecular cloning of the complimentary DNA and purification of the natural and recombinant proteins. Science. 1985;228:810-5.

Welte K, Platzer E, Lu L, Gabrilove JL, Levi E, Mertelsmann R, et al. Purification and biochemical characterization of human pluripotent hemopoietic colony stimulating factor. Proc Natl Acad Sci USA. 1985;82:1526-30.

Nagata S, Tsuchiya M, Asano S, Kaziro Y, Yamazaki T, Yamamoto O, et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature. 1986;319(6052):415-8.

Frampton JE, Lee CR, Faulds D. Filgrstim. Drugs. 1994;48(5):731-60.

Weinstock DM, Case C, Bader JL, Chao NJ, Coleman CN, Hatchett RJ, et al. Radiologic and nuclear events: contingency planning for hematologists/oncologists. Blood. 2008;111(12):5440-5.

AXIS 2: AX200 for the Treatment of Ischemic Stroke (AXIS-2). Available at http://clinicaltrials.gov/ct/show/NCT00927836.

Zang Y, Wang L, Fu Y, Song H, Zhao H, Deng M, et al. Preliminary investigation of effect of granulocyte colony stimulating factor on amyotrophic lateral sclerosis. Amy Lat Scler. 2009;4:1-2.

Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for use of WBC growth factors: American Society of Clinical Practice Guideline Update. J Clin Oncol. 2015;62:3488.